[1]刘 捷,杨玲玲,程秋霞,等.非小细胞肺癌患者血清miR-873和miR-138-5p表达水平及其与免疫微环境及预后的相关性分析[J].现代检验医学杂志,2024,39(01):23-28.[doi:10.3969/j.issn.1671-7414.2024.01.005]
　LIU Jie,YANG Lingling,CHENG Qiuxia,et al.Analysis of the Relationship between Serum miR-873 and miR-138-5p Expression and Immune Microenvironment and Prognosis in Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2024,39(01):23-28.[doi:10.3969/j.issn.1671-7414.2024.01.005]
点击复制

非小细胞肺癌患者血清miR-873和miR-138-5p表达水平及其与免疫微环境及预后的相关性分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年01期
页码:
23-28
栏目:
论著
出版日期:
2024-01-15

文章信息/Info

Title:
Analysis of the Relationship between Serum miR-873 and miR-138-5p Expression and Immune Microenvironment and Prognosis in Patients with Non-small Cell Lung Cancer
文章编号:
1671-7414（2024）01-023-06
作者:
刘 捷1; 杨玲玲1; 程秋霞2; 高 瞻2
（1. 重庆医科大学附属巴南医院呼吸与危重症医学科，重庆 400054；2. 陆军军医大学第二附属医院呼吸与危重症医学科，重庆 400037）
Author(s):
LIU Jie1;  YANG Lingling1;  CHENG Qiuxia2;  GAO Zhan2
（1.Department of Respiratory and Critical Care Medicine, Ba’nan Hospital Affiliated to Chongqing Medical University, Chongqing 400054，China; 2.Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of the Military Medical University, Chongqing 400037, China）
关键词:
非小细胞肺癌; 肿瘤免疫微环境; 微小核糖核酸-873; 微小核糖核酸-138-5p
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.01.005
文献标志码:
A
摘要:
目的　探讨血清微小核糖核酸（micro RNA，miRNAs）-873 和微小核糖核酸-138-5p 表达与非小细胞肺癌（non-small cell lung cancer，NSCLC）患者肿瘤免疫微环境（tumor immune microenvironment，TIME）以及预后的关系。方法　选择2019 年2 月～ 2021 年2 月重庆医科大学附属巴南医院收治的108 例NSCLC 患者（NSCLC 组）和65例门诊体检的健康志愿者（对照组）。实时荧光定量聚合酶链反应检测血清miR-873 和miR-138-5p 表达，多重免疫荧光染色法检测TIME 指标，出院后定期随访。Pearson 分析血清miR-873 和miR-138-5p 表达与TIME 指标的相关性，Kaplan-Meier 和COX 比例风险回归分析miR-873，miR-138-5p 与NSCLC 患者预后的关系。结果　与对照组比较，NSCLC 组血清miR-873（1.02±0.23 vs 3.15±0.82）和miR-138-5p（1.21±0.26 vs 3.54±0.92）表达降低，差异具有统计学意义（t=-25.426，-24.769，均P ＜ 0.05）。TNM 分期Ⅲ～Ⅳ期、低中度分化患者血清miR-873 和miR-138-5p 表达低于TNM 分期Ⅰ～Ⅱ期、高度分化患者（t=9.615，10.253；6.889，3.361，均P ＜ 0.05）。血清miR-873，miR-138-5p 表达与PD-1，PD-L1，CD4 和CD8 H 值呈负相关（r=-0.418 ～ -0.673，均P ＜ 0.05）。低表达miR-873 和miR-138-5p 的NSCLC患者OS生存率低于高表达miR-873 和miR-138-5p 的NSCLC患者（Log-Rankχ2=4.724，5.607，P＜ 0.05）。TNM 分期Ⅲ～Ⅳ期是NSCLC 患者不良预后的危险因素（P ＜ 0.05），miR-873，miR-138-5p 是保护因素（P ＜ 0.05）。结论　NSCLC 患者血清miR-873 和miR-138-5p 表达下调，且与TIME 以及低生存率有关。
Abstract:
Objective　To investigate the relationship between serum micro RNA（miRNAs）-873 and micro RNA-138-5p expression and tumor immune microenvironment (TIME) and prognosis in patients with non-small cell lung cancer (NSCLC). Methods　A total of 108 NSCLC patients (NSCLC group) and 65 healthy volunteers (control group) who were admitted to Ba’nan Hospital Affiliated to Chongqing Medical University from February 2019 to February 2021 were selected. Real-time quantitative fluorescence polymeric chain reaction (qRT-PCR) was used to detect the expression of miR-873 and miR-138-5p in serum, and multiple immunofluorescence staining was used to detect tumor immune microenvironment indicators. Regular follow-up was conducted after discharge. Pearson analyzed the correlation between the expression of miR-873 and miR-138-5p in serum and the TIME index, and Kaplan-Meier and COX proportional risk regression analyzed the relationship between miR- 873 and miR-138-5p and the prognosis of NSCLC patients. Results　Comparison with control group，the expressions of miR- 873（1.02±0.23 vs 3.15±0.82）and miR-138-5p（1.21±0.26 vs 3.54±0.92）in serum of NSCLC group were decreased, and the differences were statistically significant(t=-25.426，-24.769，all P < 0.05). The expressions of serum miR-873 and miR- 138-5p of patients with low-to-moderate differentiation in TNM stages Ⅲ to Ⅳ were lower than those with highly differentiated patients in TNM stages Ⅰ to Ⅱ (t=9.615，10.253；6.889，3.361，all P < 0.05). The expressions of miR-873 and miR-138-5p in serum were negatively correlated with the values of PD-1, PD-L1, CD4 and CD8 H (r=-0.418 ～ -0.673，all P < 0.05). The OS survival rate of NSCLC patients with low expression of miR-873 and miR-138-5p was lower than that of those with high expression of miR-873 and miR-138-5p (Log-Rankχ2=4.724，5.607， P < 0.05). TNM stage Ⅲ～Ⅳ was a risk factor for poor prognosis in patients with NSCLC (P < 0.05), and miR-873 and miR-138-5p were protective factors (P < 0.05). Conclusion　 The expressions of miR-873 and miR-138-5p in serum of NSCLC patients are down-regulated, which is related to TIME and low survival rate.

参考文献/References:

[1] 马彦娥, 苏虎艳, 王倩如, 等. 非小细胞肺癌组织中miR-30a 和CD73 的表达水平与预后相关性分析[J].现代检验医学杂志, 2022, 37(3): 73-78. MA Yan’e, SU Huyan, WANG Qianru, et al. Correlation analysis of tissue miR-30a and CD73 expression levels and prognosis in non-small cell lung cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 73-78.
[2] CAO Wei, CHEN Hongda, YU Yiwen, et al. Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
[3] WANG Yuchang, CHEN Rui, WA Yue, et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer [J].Front Immunol, 2022, 13:829451.
[4] XING Yingying, RUAN Guojing, NI Haiwei, et al. Tumor immune microenvironment and its related miRNAs in tumor progression [J]. Frontiers in Immunology, 2021, 12: 624725.
[5] ZOU Yuhao, ZHONG Chenming, HU Zekai, et al. MiR-873-5p: a potential molecular marker for cancer diagnosis and prognosis [J]. Frontiers in Immunology, 2021, 11: 743701.
[6] XU Weifeng, CHEN Beibei, KE Dianshan, et al. MicroRNA-138-5p targets the NFIB-snail1 axis to inhibit colorectal cancer cell migration and chemoresistance[J]. Cancer Cell International, 2020, 20: 475.
[7] 肖真真, 朱燕娟, 刘译鸿, 等. 非小细胞肺癌中医辨证分型与肿瘤免疫微环境的关系[J]. 中医肿瘤学杂志, 2022, 4(4): 14-20. XIAO Zhenzhen, ZHU Yanjuan, LIU Yihong, et al. Relationship between traditional Chinese medicine syndrome differentiation and tumor immune microenvironment in non-small cell lung cancer [J].Journal of Oncology in Chinese Medicine, 2022, 4(4): 14-20.
[8] 白日兰, 崔久嵬. 从肿瘤免疫微环境角度看免疫治疗疗效预测标志物[J]. 中国癌症防治杂志, 2021, 13(6): 585-593. BAI Rilan, CUI Jiuwei. Prognostic markers of immunotherapy efficacy from the perspective of tumor immune microenvironment[J]. Chinese Journal of Cancer Prevention and Treatment, 2021, 13(6): 585-593.
[9] MA Guofeng, ZHANG Zhilei, LI Peng, et al. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment[J].Cell Communication and Signaling, 2022, 20(1): 114.
[10] XU Zijie, CHEN Yi, MA Ling, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment[J]. Molecular Therapy, 2022, 30(10): 3133-3154.
[11] GONG Hui, FANG Lishan, LI Yifan, et al. miR-873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1[J]. Oncology Reports, 2018, 39(3): 1090-1098.
[12] CHEN Qinggui, LIN Li, XIONG Boliang, et al. MiR-873-5p targets THUMPD1 to inhibit gastric cancer cell behavior and chemoresistance[J]. Journal of Gastrointestinal Oncology, 2021, 12(5): 2061-2072.
[13] ZHU Yufeng, ZHANG Xiaojian, QI Ming, et al. MiR-873-5p inhibits the progression of colon cancer via repression of tumor suppressor candidate 3/AKT signaling[J]. Journal of Gastroenterology and Hepatology, 2019, 34(12): 2126-2134.
[14] WANG Zhenglin, LIU Wei, WANG Cong, et al. MiR-873-5p inhibits cell migration and invasion of papillary thyroid cancer via regulation of CXCL16[J]. Onco Targets and Therapy, 2020, 13: 1037-1046.
[15] YU Yaying, XING Yanwei, ZHANG Qian, et al. Soy isoflavone genistein inhibits hsa_circ_0031250/miR-873-5p/FOXM1 axis to suppress non-small-cell lung cancer progression[J]. IUBMB Life, 2021, 73(1): 92-107.
[16] GAO Lanlan, GUO Qianqian, LI Xiaoman, et al. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells [J]. EBioMedicine, 2019, 41: 395-407.
[17] PERROT I, BLANCHARD D, FREYMOND N, et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage[J]. Journal of Immunology, 2007, 178(5): 2763-2769.
[18] ZHANG Hao, LIU Yan, XU Zhihong, et al. MiR-873 and miR-105-2 may affect the tumour microenvironment and are potential biomarkers for lung adenocarcinoma [J]. International Journal of General Medicine, 2022, 15: 3433-3445.
[19] XUN Jing, DU Lingfang, GAO Ruifang, et al. Cancerderived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B[J]. Theranostics, 2021, 11(14): 6847-6859.
[20] HUANG Hui, XIONG Ying, WU Zhensheng, et al. MIR-138-5P inhibits the progression of prostate cancer by targeting FOXC1[J]. Molecular Genetics & Genomic Medicine, 2020, 8(4): e1193.
[21] ZHANG Wei, LIAO Kai, LIU Dongning. MiR-138-5p inhibits the proliferation of gastric cancer cells by targeting DEK [J]. Cancer Management and Research, 2020, 12: 8137-8147.
[22] HE Zhenwei, RUAN Xuelei, LIU Xiabai, et al. FUS/circ_002136/miR-138-5p/SOX13 feedback loop regulates angiogenesis in Glioma[J]. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 65.
[23] WU Jia’en, HAN Xuejia, YANG Xiancong, et al. MiR-138-5p suppresses the progression of lung cancer by targeting SNIP1[J]. Thoracic Cancer, 2023, 14(6): 612-623.
[24] XING Shigang, XU Qinghua, FAN Xinlei, et al. Downregulation of miR-138-5p promotes non-small cell lung cancer progression by regulating CDK8[J].Molecular Medicine Reports, 2019, 20(6): 5272-5278.
[25] RASOOLNEZHAD M, SAFARALIZADEH R, HOSSEINPOURFEIZI M A, et al. MiRNA-138-5p: A strong tumor suppressor targeting PD-L-1 inhibits proliferation and motility of breast cancer cells and induces apoptosis [J]. European Journal of Pharmacology, 2021, 896: 173933.
[26] SONG Nannan, LI Peng, SONG Pingping, et al. MicroRNA-138-5p suppresses non-small cell lung cancer cells by targeting PD-L1/PD-1 to regulate tumor microenvironment [J]. Frontiers in Cell and Developmental Biology, 2020, 8: 540.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(01):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(01):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(01):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(01):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目：重庆市巴南区科学技术科研项目（2021-41）：IGS/LABA 直接转换为双支扩剂欧乐欣治疗COPD 患者的有效性及安全性研究。
作者简介：刘捷（1989-），男，硕士，主治医师，研究方向: 肺部肿瘤治疗，E-mail：1572309385@163.com。
通讯作者：杨玲玲（1985-），女，本科， 主治医师，研究方向: 肺癌诊治，E-mail：1860230437@163.com。
更新日期/Last Update: 2024-01-15